Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications

26 Nov 2024

Abstract excerpt

Non-muscle-invasive bladder cancer (NMIBC) often recurs and can progress to MIBC due to resistance to treatments like intravesical chemotherapy or Bacillus Calmette-Guérin (BCG). Therefore, we established the Gemcitabine-Resistant Cells (GRCs) to study the molecular evolution under external pressure. A 63-gene Chemoresistance-Motility (CrM) signature was created to identify stage-specific traits of GRCs. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39608442
DOI: 10.1016/j.canlet.2024.217339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implicationsPMID 39608442Read ↗

Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cellsSemantic proximity Read ↗

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Semantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity Read ↗

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelSemantic proximity Read ↗

Evolution of Urothelial Bladder Cancer in the Context of Molecular ClassificationsSemantic proximity Read ↗

Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancerSemantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Molecular subtyping of invasive bladder cancer: time to divide and rule?Semantic proximity Read ↗

Prognostic Factors of Non-Muscle Invasive Bladder Cancer: A Study Based on Next-generation SequencingSemantic proximity Read ↗

An EMT‐related gene signature for the prognosis of human bladder cancerSemantic proximity Read ↗

Key signaling pathways in the muscle‐invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.